Intermittent preventive treatment with Sulfadoxine pyrimethamine for malaria: a global overview and challenges affecting optimal drug uptake in pregnant women

References

• World malaria report 2021, (n.d.) [cited 2021 Dec 20]. Available from:https://www.who.int/publications-detail-redirect/9789240040496
   Google Scholar
• White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383(9918):723–735.
   PubMed Web of Science ®Google Scholar
• Moore BR, Benjamin JM, Tobe R, et al. A randomized open-label evaluation of the antimalarial prophylactic efficacy of azithromycin-piperaquine versus sulfadoxine-pyrimethamine in pregnant papua new guinean women. Antimicrob Agents Chemother. 2019;63(10). DOI:10.1128/AAC.00302-19
   Web of Science ®Google Scholar
• Rogerson SJ, Desai M, Mayor A, et al. Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. Lancet Infect Dis. 2018;18(4):e107–e118.
   PubMed Web of Science ®Google Scholar
• Pincelli A, Neves PAR, Lourenço BH, et al.The hidden burden of plasmodium vivax malaria in pregnancy in the amazon: an observational study in northwestern Brazil. Am J Trop Med Hyg. 2018;99(1):73–83. DOI:10.4269/ajtmh.18-0135.
   PubMed Web of Science ®Google Scholar
• Hartman TK, Rogerson SJ, Fischer PR. The impact of maternal malaria on newborns. Ann Trop Paediatr. 2010;30(4):271–282.
   PubMed Web of Science ®Google Scholar
• WHO | a strategic framework for malaria prevention and control during pregnancy in the African region (archived), WHO. (n.d.) [cited 2021 Jan 13]. Available from:http://www.who.int/malaria/publications/atoz/afr_mal_04_01/en/
   Google Scholar
• WHO | Intermittent preventive treatment in pregnancy (IPTp), WHO. (n.d.) [cited 2021 Jan 13]. Available from:http://www.who.int/malaria/areas/preventive_therapies/pregnancy/en/
   Google Scholar
• WHO | World Malaria Report 2010, WHO. (n.d.).
   Google Scholar
• Ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007;297(23):2603–2616.
   PubMed Web of Science ®Google Scholar
• Mlugu EM, Minzi O, Asghar M, et al. Effectiveness of sulfadoxine–pyrimethamine for intermittent preventive treatment of malaria and adverse birth outcomes in pregnant women, pathogens. 2020;9:207. DOI:10.3390/pathogens9030207
   Google Scholar
• Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309(6):594–604.
   PubMed Web of Science ®Google Scholar
• Anto F, Agongo IH, Asoala V, et al. Intermittent preventive treatment of malaria in pregnancy: assessment of the sulfadoxine-pyrimethamine three-dose policy on birth outcomes in rural northern Ghana. J Trop Med. 2019;2019:6712685.
   PubMed Web of Science ®Google Scholar
• Mace KE, Chalwe V, Katalenich BL, et al. Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa. Zambia, Malar J. 2015;14. DOI:10.1186/s12936-015-0576-8
   Web of Science ®Google Scholar
• Nekaka R, Nteziyaremye J, Oboth P, et al. Malaria preventive practices and delivery outcomes: a cross-sectional study of parturient women in a tertiary hospital in Eastern Uganda. PLoS One. 2020;15(8):e0237407.
   PubMed Web of Science ®Google Scholar
• Mpogoro FJ, Matovelo D, Dosani A, et al. Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in geita district, north-western Tanzania. Malar J. 2014;13(1):455.
   PubMedGoogle Scholar
• Pell C, Straus L, Andrew EVW, et al. Social and cultural factors affecting uptake of interventions for malaria in pregnancy in Africa: a systematic review of the qualitative research. PLoS One. 2011;6(7):e22452.
   PubMed Web of Science ®Google Scholar
• Mchwampaka WM, Tarimo D, Chacky F, et al. Factors affecting uptake of ≥ 3 doses of sulfadoxine-pyrimethamine for malaria prevention in pregnancy in selected health facilities, Arusha region, Tanzania. BMC Pregnancy Childbirth. 2019;19(1). DOI:10.1186/s12884-019-2592-0
   PubMed Web of Science ®Google Scholar
• van Eijk AM, Larsen DA, Kayentao K, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(5):546–556.
   PubMed Web of Science ®Google Scholar
• Naidoo I, Roper C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol. 2013;29(10):505–515.
   PubMed Web of Science ®Google Scholar
• Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017;7(1):7389.
   PubMedGoogle Scholar
• Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5(3):101–117.
   PubMed Web of Science ®Google Scholar
• Desai M, Ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):93–104.
   PubMed Web of Science ®Google Scholar
• World malaria report 2020, (n.d.) [cited 2021 Jan 13]. Available from:https://www.who.int/publications-detail-redirect/9789240015791
   Google Scholar
• Kattenberg JH, Tahita CM, Versteeg IAJ, et al. Evaluation of antigen detection tests, microscopy, and polymerase chain reaction for diagnosis of malaria in peripheral blood in asymptomatic pregnant women in Nanoro, Burkina Faso. Am J Trop Med Hyg. 2012;87(2):251–256.
   PubMed Web of Science ®Google Scholar
• Matangila JR, Lufuluabo J, Ibalanky AL, et al. Asymptomatic Plasmodium falciparum infection is associated with anaemia in pregnancy and can be more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, democratic republic of the Congo. Malar J. 2014;13(1):132.
   PubMedGoogle Scholar
• Siame MN, Mharakurwa S, Chipeta J, et al. High prevalence of dhfr and dhps molecular markers in Plasmodium falciparum in pregnant women of Nchelenge district, Northern Zambia. Malar J. 2015;14(1). DOI:10.1186/s12936-015-0676-5
   PubMedGoogle Scholar
• Mbonye AK, Birungi J, Yanow SK, et al. Prevalence of Plasmodium falciparum Resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda. Antimicrob Agents Chemother. 2015;59(9):5475–5482.
   PubMed Web of Science ®Google Scholar
• Boudová S, Divala T, Mawindo P, et al. The prevalence of malaria at first antenatal visit in Blantyre, Malawi declined following a universal bed net campaign. Malar J. 2015;14(1):422.
   PubMedGoogle Scholar
• Chaponda EB, Chandramohan D, Michelo C, et al. High burden of malaria infection in pregnant women in a rural district of Zambia: a cross-sectional study. Malar J. 2015;14(1). DOI:10.1186/s12936-015-0866-1
   PubMedGoogle Scholar
• Maïga-Ascofaré O, Rakotozandrindrainy R, Girmann M, et al. Molecular epidemiology and seroprevalence in asymptomatic Plasmodium falciparum infections of Malagasy pregnant women in the highlands. Malar J. 2015;14(1):188.
   PubMedGoogle Scholar
• Williams J, Njie F, Cairns M, et al. Non-Falciparum malaria infections in pregnant women in West Africa. Malar J. 2016;15(1). DOI:10.1186/s12936-016-1092-1
   Google Scholar
• Francine N, Damien B, Anna F, et al. Characterization of asymptomatic Plasmodium falciparum infection and its risk factors in pregnant women from the republic of Congo. Acta Trop. 2016;153:111–115.
   PubMed Web of Science ®Google Scholar
• Monjol BE, Useh MF. Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria. Ann Parasitol. 2017;63(4):323–330.
   PubMedGoogle Scholar
• Martínez-Pérez G, Lansana DP, Omeonga S, et al. Prevalence of Plasmodium falciparum infection among pregnant women at first antenatal visit in post-Ebola Monrovia, Liberia. Malar J. 2018;17(1):357.
   PubMedGoogle Scholar
• Ojurongbe O, Nguetse CN, Fayemiwo SA, et al. High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine. Pathog Glob Health. 2018;112(2):86–92.
   PubMed Web of Science ®Google Scholar
• Kayiba NK, Yobi DM, Tchakounang VRK, et al. Evaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of Plasmodium falciparum in kingasani hospital, kinshasa in the democratic republic of Congo. Infect Genet Evol. 2021;94:105009.
   PubMed Web of Science ®Google Scholar
• Doritchamou JYA, Akuffo RA, Moussiliou A, et al. Submicroscopic placental infection by non-falciparum Plasmodium spp. PLoS Negl Trop Dis. 2018;12(2):e0006279.
   PubMed Web of Science ®Google Scholar
• Anabire NG, Aryee PA, Abdul-Karim A, et al. Prevalence of malaria and hepatitis B among pregnant women in northern Ghana: comparing RDTs with PCR. PLoS One. 2019;14:e0210365.
   PubMed Web of Science ®Google Scholar
• Mlugu EM, Minzi O, Kamuhabwa AAR, et al. Prevalence and correlates of asymptomatic malaria and anemia on first antenatal care visit among pregnant women in southeast, Tanzania. Int J Environ Res Public Health. 2020;17(9):3123.
   PubMed Web of Science ®Google Scholar
• Gikunju SW, Agola EL, Ondondo RO, et al. Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at msambweni county referral hospital, Kwale County, Kenya. Malar J. 2020;19(1):190.
   PubMedGoogle Scholar
• McGregor D, Texeira da Silva E, Grignard L, et al. The epidemiology of Plasmodium falciparum malaria in the Bijagos Islands of Guinea-bissau. Am J Trop Med Hyg. 2021;tpmd201029. DOI:10.4269/ajtmh.20-1029
   PubMedGoogle Scholar
• Bardají A, Martínez-Espinosa FE, Arévalo-Herrera M, et al. PregVax study group, burden and impact of Plasmodium vivax in pregnancy: a multi-centre prospective observational study. PLoS Negl Trop Dis. 2017;11(6):e0005606.
   PubMed Web of Science ®Google Scholar
• Vásquez A-M, Zuluaga-Idárraga L, Arboleda M, et al. Malaria in pregnancy in endemic regions of colombia: high frequency of asymptomatic and peri-urban infections in pregnant women with malaria. Infect Dis Obstet Gynecol. 2020;2020:2750258.
   PubMedGoogle Scholar
• Vásquez AM, Vélez G, Medina A, et al. Evaluation of highly sensitive diagnostic tools for the detection of P. falciparum in pregnant women attending antenatal care visits in Colombia. BMC Pregnancy Childbirth. 2020;20(1):440.
   PubMed Web of Science ®Google Scholar
• Dombrowski JG, Barateiro A, Peixoto EPM, et al. Adverse pregnancy outcomes are associated with Plasmodium vivax malaria in a prospective cohort of women from the Brazilian Amazon. PLoS Negl Trop Dis. 2021;15(4):e0009390.
   PubMed Web of Science ®Google Scholar
• Gavina K, Gnidehou S, Arango E, et al. clinical outcomes of submicroscopic infections and correlates of protection of VAR2CSA antibodies in a longitudinal study of pregnant women in Colombia. Infect Immun. 2018;86:e00797–17. DOI:10.1128/IAI.00797-17.
   PubMed Web of Science ®Google Scholar
• Barber BE, Bird E, Wilkes CS, et al. Plasmodium knowlesi malaria during pregnancy. J Infect Dis. 2015;211(7):1104–1110.
   PubMed Web of Science ®Google Scholar
• Briand V, Le Hesran J-Y, Mayxay M, et al. Prevalence of malaria in pregnancy in southern Laos: a cross-sectional survey. Malar J. 2016;15(1). DOI:10.1186/s12936-016-1492-2
   PubMedGoogle Scholar
• Elbadry MA, Tagliamonte MS, Raccurt CP, et al. Submicroscopic malaria infections in pregnant women from six departments in Haiti. Trop Med Int Health. 2017;22(8):1030–1036.
   PubMed Web of Science ®Google Scholar
• Khan WA, Galagan SR, Prue CS, et al. Asymptomatic Plasmodium falciparum malaria in pregnant women in the chittagong hill districts of Bangladesh. PLoS One. 2014;9(5):e98442.
   PubMed Web of Science ®Google Scholar
• Sohail M, Shakeel S, Kumari S, et al. Prevalence of malaria infection and risk factors associated with anaemia among pregnant women in semiurban community of Hazaribag, Jharkhand, India. Biomed Res Int. 2015;2015:740512.
   PubMed Web of Science ®Google Scholar
• Tan SO, McGready R, Zwang J, et al. Thrombocytopaenia in pregnant women with malaria on the Thai-burmese border. Malar J. 2008;7(1):209.
   PubMedGoogle Scholar
• WHO Guidelines for malaria, (n.d.) [cited 2022 Jul 15]. Available from:https://www.who.int/publications-detail-redirect/guidelines-for-malaria
   Google Scholar
• Schultz LJ, Steketee RW, Chitsulo L, et al. Evaluation of maternal practices, efficacy, and cost-effectiveness of alternative antimalarial regimens for use in pregnancy: chloroquine and sulfadoxine-pyrimethamine. Am J Trop Med Hyg. 1996;55(1_Suppl):87–94.
   PubMed Web of Science ®Google Scholar
• Schultz LJ, Steketee RW, Chitsulo L, et al. Antimalarials during pregnancy: a cost-effectiveness analysis. Bull World Health Organ. 1995;73(2):207–214.
   PubMed Web of Science ®Google Scholar
• Brabin BJ, Verhoeff FH, Kazembe P, et al. Antimalarial drug policy in Malawi. Null. 1997;91:S113–S115.
   Google Scholar
• Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998;59(5):813–822.
   PubMed Web of Science ®Google Scholar
• Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg. 1994;51(5):515–522.
   PubMed Web of Science ®Google Scholar
• Verhoeff FH, Brabin BJ, Chimsuku L, et al. An evaluation of the effects of intermittent sulfadoxine—pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol. 1998;92(2):141–150.
   PubMed Web of Science ®Google Scholar
• S. WHO Expert Committee on Malaria (1998 : Geneva, W.H. Organization, WHO Expert Committee on Malaria : twentieth report, World Health Organization; 2000 [cited 2022 Jul 14]. Available from:https://apps.who.int/iris/handle/10665/42247
   Google Scholar
• WHO | World Malaria Report 2010, WHO. (n.d.) [cited 2021 Jan 13]. Available from:https://www.who.int/malaria/publications/atoz/9789241564106/en/
   Google Scholar
• van Eijk AM, Hill J, Larsen DA, et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009–11. Lancet Infect Dis. 2013;13(12):1029–1042.
   PubMed Web of Science ®Google Scholar
• Nabarro D. Roll back malaria. Parassitologia. 1999;41(1–3):501–504.
   PubMedGoogle Scholar
• World malaria Report 2012, WHO. (2012) [cited 2020 Oct 25]. Available from:https://www.who.int/malaria/publications/world_malaria_report_2012/en/
   Google Scholar
• Ahmed R, Poespoprodjo JR, Syafruddin D, et al. Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial. Lancet Infect Dis. 2019;19(9):973–987.
   PubMed Web of Science ®Google Scholar
• WHO | World Malaria Report 2015, WHO. (n.d.) [cited 2020 Oct 25]. Available from:http://www.who.int/malaria/publications/world-malaria-report-2015/en/
   Google Scholar
• Pons-Duran C, Llach M, Sacoor C, et al. Coverage of intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries: findings from household surveys. Int J Epidemiol. 2021;50(2):550–559.
   PubMed Web of Science ®Google Scholar
• Bertin G, Briand V, Bonaventure D, et al. Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J. 2011;10(1). 196. DOI:https://doi.org/10.1186/1475-2875-10-196.
   Google Scholar
• Ruizendaal E, Tahita MC, Geskus RB, et al. Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro. Burkina Faso, Malar J. 2017;16:179.
   PubMed Web of Science ®Google Scholar
• Lucchi NW, Okoth SA, Komino F, et al. Increasing prevalence of a novel triple-mutant dihydropteroate synthase genotype in Plasmodium falciparum inWestern Kenya. Antimicrob Agents Chemother. 2015;59(7):3995–4002.
   PubMed Web of Science ®Google Scholar
• Guidelines for the treatment of malaria - Third edition, (n.d.) [cited 2021 Jan 14]. Available from:https://www.who.int/publications-detail-redirect/9789241549127
   Google Scholar
• Bauserman M, Conroy AL, North K, et al. An overview of malaria in pregnancy. Semin Perinatol. 2019;43(5):282–290.
   PubMed Web of Science ®Google Scholar
• D’Alessandro U, Hill J, Tarning J, et al. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018;18(4):e133–e146.
   PubMed Web of Science ®Google Scholar
• Yimam Y, Nateghpour M, Mohebali M, et al. A systematic review and meta-analysis of asymptomatic malaria infection in pregnant women in Sub-Saharan Africa: a challenge for malaria elimination efforts. PLoS One. 2021;16(4):e0248245.
   PubMed Web of Science ®Google Scholar
• Fried M, Muehlenbachs A, Duffy PE. Diagnosing malaria in pregnancy: an update, expert review of anti-infective therapy. 2012;10:1177–1187. DOI:10.1586/eri.12.98
   Google Scholar
• Kovacs SD, Rijken MJ, Stergachis A. Treating severe malaria in pregnancy: a review of the evidence. Drug Saf. 2015;38(2):165–181.
   PubMed Web of Science ®Google Scholar
• Saito M, Gilder ME, McGready R, et al. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018;17(11):1129–1144.
   PubMed Web of Science ®Google Scholar
• D’Alessandro S, Menegola E, Parapini S, et al. Safety of artemisinin derivatives in the first trimester of pregnancy: a controversial story. Molecules. 2020;25(15):3505.
   PubMed Web of Science ®Google Scholar
• Dellicour S, Sevene E, McGready R, et al. First-Trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med. 2017;14(5):e1002290.
   PubMed Web of Science ®Google Scholar
• Augusto O, Stergachis A, Dellicour S, et al. First trimester use of artemisinin-based combination therapy and the risk of low birth weight and small for gestational age. Malar J. 2020;19(1). DOI:10.1186/s12936-020-03210-y
   PubMed Web of Science ®Google Scholar
• Rouamba T, Sondo P, Derra K, et al. Optimal approach and strategies to strengthen pharmacovigilance in sub-Saharan Africa: a cohort study of patients treated with first-line artemisinin-based combination therapies in the nanoro health and demographic surveillance system, Burkina Faso. Drug Des Devel Ther. 2020;14:1507–1521.
   PubMed Web of Science ®Google Scholar
• World malaria report 2019, (n.d.) [cited 2020 Oct 25]. Available from:https://www.who.int/publications-detail-redirect/9789241565721
   Google Scholar
• Hill J, D’Mello-Guyett L, Hoyt J, et al. Women’s access and provider practices for the case management of malaria during pregnancy: a systematic review and meta-analysis. PLoS Med. 2014;11(8):e1001688.
   PubMed Web of Science ®Google Scholar
• Okethwangu D, Opigo J, Atugonza S, et al. Factors associated with uptake of optimal doses of intermittent preventive treatment for malaria among pregnant women in Uganda: analysis of data from the Uganda demographic and Health Survey. Malar J. 2016;18(1):250.
   Google Scholar
• Azizi SC. Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-pyrimethamine in Malawi after adoption of updated World Health Organization policy: an analysis of demographic and health survey 2015–2016. BMC Public Health. 2020;20(1). DOI:https://doi.org/10.1186/s12889-020-08471-5
   Google Scholar
• Eisele TP, Larsen DA, Anglewicz PA, et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Lancet Infect Dis. 2012;12(12):942–949.
   PubMed Web of Science ®Google Scholar
• Nyaaba GN, Olaleye AO, Obiyan MO, et al. A socio-ecological approach to understanding the factors influencing the uptake of intermittent preventive treatment of malaria in pregnancy (IPTp) in south-western Nigeria. PLoS One. 2021;16(3):e0248412.
   PubMed Web of Science ®Google Scholar
• Mutanyi JA, Onguru DO, Ogolla SO, et al. Determinants of the uptake of intermittent preventive treatment of malaria in pregnancy with sulphadoxine pyrimethamine in Sabatia sub county, western Kenya. Infect Dis Poverty. 2021;10(1):106.
   PubMed Web of Science ®Google Scholar
• Balami AD, Md Said S, Mohd Zulkefli NA, et al. Determinants of uptake of first dose of intermittent preventive treatment among pregnant women in a secondary health centre in Maiduguri, Nigeria. BMC Pregnancy Childbirth. 2020;20(1):726.
   PubMed Web of Science ®Google Scholar
• Wafula ST, Mendoza H, Nalugya A, et al. Determinants of uptake of malaria preventive interventions among pregnant women in eastern Uganda. Malar J. 2021;20(1):5.
   PubMed Web of Science ®Google Scholar
• Hill J, Hoyt J, van Eijk AM, et al. Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2013;10(7):e1001488.
   PubMed Web of Science ®Google Scholar
• Dun-Dery F, Meissner P, Beiersmann C, et al. Uptake challenges of intermittent preventive malaria therapy among pregnant women and their health care providers in the upper west region of Ghana: a mixed-methods study. Parasite Epidemiol Control. 2021;15:e00222.
   PubMedGoogle Scholar
• Oppong FB, Gyaase S, Zandoh C, et al. Intermittent preventive treatment of pregnant women in kintampo area of Ghana with sulphadoxine-pyrimethamine (SP): trends spanning 2011 and 2015. BMJ Open. 2019;9(6):e027946.
   PubMed Web of Science ®Google Scholar
• Awantang GN, Babalola SO, Koenker H, et al. Malaria-Related ideational factors and other correlates associated with intermittent preventive treatment among pregnant women in Madagascar. Malar J. 2018;17(1):176.
   PubMedGoogle Scholar
• Olugbade OT, Ilesanmi OS, Gubio AB, et al. Socio-Demographic and regional disparities in utilization of intermittent preventive treatment for malaria in pregnancy - Nigeria demographic health survey 2013. Pan Afr Med J. 2019;32:13.
   PubMedGoogle Scholar
• Darteh EKM, Buabeng I, Akuamoah-Boateng C. Uptake of intermittent preventive treatment in pregnancy for malaria: further analysis of the 2016 Ghana malaria indicator survey. J Public Health (Berl). 2020. DOI:10.1007/s10389-020-01206-1
   PubMed Web of Science ®Google Scholar
• Exavery A, Mbaruku G, Mbuyita S, et al. Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. Malar J. 2014;13(1):22.
   PubMedGoogle Scholar
• Sangho O, Tounkara M, Whiting-Collins LJ, et al. Determinants of intermittent preventive treatment with sulfadoxine–pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey. Malar J. 2021;20(1):231.
   PubMed Web of Science ®Google Scholar
• Ndu A, Mbachu C, Anitube O, et al. Inequities in the use of sulphadoxine-pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. Malawi Med J. 2020;32(1):45–51.
   PubMed Web of Science ®Google Scholar
• Amoran OE, Ariba AA, Iyaniwura CA. Determinants of intermittent preventive treatment of malaria during pregnancy (IPTp) utilization in a rural town in Western Nigeria, reprod health. 2012;9:12. DOI:10.1186/1742-4755-9-12
   Google Scholar
• Amankwah S, Anto F. Factors associated with uptake of intermittent preventive treatment of malaria in pregnancy: a cross-sectional study in private health facilities in Tema Metropolis, Ghana. J Trop Med. 2019;2019:9278432.
   PubMed Web of Science ®Google Scholar
• Ameh S, Owoaje E, Oyo-Ita A, et al. Barriers to and determinants of the use of intermittent preventive treatment of malaria in pregnancy in cross river state, Nigeria: a cross-sectional study. BMC Pregnancy Childbirth. 2016;16(1). DOI:10.1186/s12884-016-0883-2
   PubMedGoogle Scholar
• Nkunzimana E, Babale MS. Knowledge and utilisation of intermittent preventive treatment of malaria among pregnant women in muramvya health district, Burundi, 2018. East Afr Health Res J. 2020;4(1):81–91.
   PubMedGoogle Scholar
• Akpa CO, Akinyemi JO, Umeokonkwo CD, et al. Uptake of intermittent preventive treatment for malaria in pregnancy among women in selected communities of Ebonyi state, Nigeria. BMC Pregnancy Childbirth. 2019;19(1). DOI:10.1186/s12884-019-2629-4
   PubMed Web of Science ®Google Scholar
• Azizi SC, Chongwe G, Chipukuma H, et al. Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-pyrimethamine (IPTp-SP) among postpartum women in Zomba district, Malawi: a cross-sectional study. BMC Pregnancy Childbirth. 2018;18(1):108.
   PubMedGoogle Scholar
• Sherrard-Smith E, Hogan AB, Hamlet A, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med. 2020;26(9):1411–1416.
   PubMed Web of Science ®Google Scholar
• De-Gaulle VF, Magnussen P, Kamgno J, et al. Assessing health system factors affecting access and delivery of IPTp-SP and ITN to pregnant women attending ANC clinics in Ghana. BMC Health Serv Res. 2021;21(1):1056.
   PubMed Web of Science ®Google Scholar
• Bello OO, Oni O. Health workers’ awareness and knowledge of current recommendation of intermittent preventive treatment in pregnancy in south-western Nigeria. Ethiop J Health Sci. 2020;30(1):125–134.
   PubMed Web of Science ®Google Scholar
• Olaleye AO, Walker O. Impact of health systems on the implementation of intermittent preventive treatment for malaria in pregnancy in sub-Saharan Africa: a narrative synthesis. Trop Med Infect Dis. 2020;5(3):E134.
   PubMedGoogle Scholar
• Aberese-Ako M, Magnussen P, Ampofo GD, et al. An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context. PLoS One. 2021;16(10):e0257666.
   PubMed Web of Science ®Google Scholar
• Dhama K, Khan S, Tiwari R, et al. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020;33(4). DOI:10.1128/CMR.00028-20
   PubMed Web of Science ®Google Scholar
• Chiodini J. COVID-19 and the impact on travel health advice. Travel Med Infect Dis. 2020;36:101824.
   PubMed Web of Science ®Google Scholar
• Quakyi I, Tornyigah B, Houze P, et al. High uptake of intermittent preventive treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana, scientific reports. 2019;9:19034. DOI:10.1038/s41598-019-55046-5
   Google Scholar
• Fagbemi KA, Adebusuyi SA, Nderu D, et al. Analysis of sulphadoxine–pyrimethamine resistance-associated mutations in Plasmodium falciparum isolates obtained from asymptomatic pregnant women in Ogun state, southwest Nigeria, infection. Gene Evolut. 2020;85:104503.
   PubMed Web of Science ®Google Scholar
• Ngondi JM, Ishengoma DS, Doctor SM, et al. Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the lake and southern zones, Tanzania, using pooling and next-generation sequencing. Malar J. 2017;16(1):236.
   PubMedGoogle Scholar
• Gutman J, Kalilani L, Taylor S, et al. The A581 G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthetase reduces the effectiveness of sulfadoxine-pyrimethamine preventive therapy in malawian pregnant women. J Infect Dis. 2015;211(12):1997–2005.
   PubMed Web of Science ®Google Scholar
• Saito M, Briand V, Min AM, et al. Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. Lancet Child Adolesc Health. 2020;4(10):761–774.
   PubMedGoogle Scholar
• WHO | Co-trimoxazole prophylaxis for malaria and bacterial infections in people with HIV, WHO. (n.d.) [cited 2021 Jan 14]. Available from:https://www.who.int/hiv/topics/arv/cotrimoxazole_factsheet_dec2014/en/
   Google Scholar
• WHO | Malaria and HIV Interactions and their Implications for Public Health Policy, WHO. (n.d.) [cited 2021 Jan 14]. https://www.who.int/hiv/pub/prev_care/malaria/en/
   Google Scholar
• Desai M, Hill J, Fernandes S, et al. Prevention of malaria in pregnancy. Lancet Infect Dis. 2018;18(4):e119–e132.
   PubMed Web of Science ®Google Scholar
• Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis. AIDS. 2020;34(5):761–776.
   PubMed Web of Science ®Google Scholar
• Kajubi R, Ochieng T, Kakuru A, et al. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. Lancet. 2019;393:1428–1439.
   PubMed Web of Science ®Google Scholar
• Roh ME, Kuile FOT, Rerolle F, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. Lancet Glob Health. 2020;8(7):e942–e953.
   PubMed Web of Science ®Google Scholar
• Olaleye A, Okusanya BO, Oduwole O, et al. A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. Int J Gynaecol Obstet. 2019;146(1):43–55.
   PubMed Web of Science ®Google Scholar
• Divala TH, Mungwira RG, Mawindo PM, et al. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. Lancet Infect Dis. 2018;18(10):1097–1107.
   PubMed Web of Science ®Google Scholar
• Kimani J, Phiri K, Kamiza S, et al. Efficacy and safety of Azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa: an open-label, randomized trial. PLoS One. 2016;11(6):e0157045.
   PubMed Web of Science ®Google Scholar
• Akinyotu O, Bello F, Abdus-Salam R, et al. A randomized controlled trial of azithromycin and sulphadoxine–pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus–positive women. Trans R Soc Trop Med Hyg. 2019;113(8):463–470.
   PubMed Web of Science ®Google Scholar
• Desai M, Gutman J, L’Lanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386(10012):2507–2519.
   PubMed Web of Science ®Google Scholar
• Esu E, Berens-Riha N, Pritsch M, et al. Intermittent screening and treatment with artemether–lumefantrine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. Malar J. 2018;17(1):251.
   PubMedGoogle Scholar
• Teo A, Randall LM, Madanitsa M, et al. Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women. Sci Rep. 2019;9(1):7878.
   PubMedGoogle Scholar
• Tagbor H, Cairns M, Bojang K, et al. A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy. PLoS One. 2015;10(8):e0132247.
   PubMed Web of Science ®Google Scholar
• Tagbor H, Bruce J, Agbo M, et al. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. PLoS One. 2010;5(12):e14425.
   PubMed Web of Science ®Google Scholar
• Madanitsa M, Kalilani L, Mwapasa V, et al. Scheduled intermittent screening with rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. PLoS Med. 2016;13:e1002124.
   PubMed Web of Science ®Google Scholar
• Awine T, Belko MM, Oduro AR, et al. The risk of malaria in Ghanaian infants born to women managed in pregnancy with intermittent screening and treatment for malaria or intermittent preventive treatment with sulfadoxine/pyrimethamine. Malar J. 2016;15(1):46.
   PubMedGoogle Scholar
• Gutman JR, Khairallah C, Stepniewska K, et al. Intermittent screening and treatment with artemisinin-combination therapy versus intermittent preventive treatment with sulphadoxine- pyrimethamine for malaria in pregnancy: a systematic review and individual participant data meta-analysis of randomised clinical trials. EClinicalMedicine. 2021;41:101160.
   PubMedGoogle Scholar
• Hill J, Ouma P, Oluoch S, et al. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya. Malar J. 2020;19(1):433.
   PubMed Web of Science ®Google Scholar
• Webster J, Ansariadi FHB, Landuwulang CUR, et al. Evaluation of the implementation of single screening and treatment for the control of malaria in pregnancy in Eastern Indonesia: a systems effectiveness analysis. Malar J. 2018;17(1):310.
   PubMedGoogle Scholar
• Kuepfer I, Mishra N, Bruce J, et al. Effectiveness of intermittent screening and treatment for the control of malaria in pregnancy: a cluster randomised trial in India. BMJ Glob Health. 2019;4(4):e001399.
   PubMed Web of Science ®Google Scholar
• Scott S, D’Alessandro U, Kendall L, et al.Community-based malaria screening and treatment for pregnant women receiving standard intermittent preventive treatment with Sulfadoxine-pyrimethamine: a multicenter (The Gambia, Burkina Faso, and Benin) cluster-randomized controlled trial. Clin Infect Dis. 2019;68(4):586–596. DOI:10.1093/cid/ciy522.
   PubMed Web of Science ®Google Scholar
• Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21(8):1120–1128.
   PubMed Web of Science ®Google Scholar
• Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602–1608.
   PubMed Web of Science ®Google Scholar
• Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385(13):1163–1171.
   PubMed Web of Science ®Google Scholar
• WHO Malaria Policy Advisory Committee and SecretariatMalaria policy advisory committee to the WHO: conclusions and recommendations of eighth biannual meeting (september 2015. Malar J. 2016;15(1):117. DOI:10.1186/s12936-016-1169-x.
   PubMedGoogle Scholar